TB-500
Synthetic fragment of thymosin beta-4. TB-500 is not FDA approved for any use.
Key facts
- Class
- Synthetic fragment of thymosin beta-4
- Also called
- TB4, thymosin beta-4
- Vial sizes sold
- 2 mg, 5 mg, 10 mg, 20 mg
- Community-reported sizes
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- PCAC vote
- 8–6 for 503A
- Jul 2026, not final
- WADA
- Prohibited (S2.3)
- In and out of competition
TB-500 guides
Explained
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Hair | Not in our ledger | Not in our ledger | 1 | Animal evidence, 2 of 4PloS one 2015, PMID 26083021 |
| Eyes | Not in our ledger | Not in our ledger | 3 | Human RCT evidence, 4 of 4Cornea 2015, PMID 25826322 |
| Inflammation | 78 | 80 | 2 | Human RCT evidence, 4 of 4Microbial biotechnology 2021, PMID 34318587 |
| Injury recovery | 52 | 71 | 7 | Human RCT evidence, 4 of 4Annals of the New York Academy of Sciences 2010, PMID 20536470 |
| Skin | 5 | 10 | 3 | Human RCT evidence, 4 of 4Microbial biotechnology 2021, PMID 34318587 |
| Allergies | 4 | 1 | 0 | No graded study for this goal |
| Bone health | 1 | 0 | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
TB-500 is a fragment; most "thymosin beta-4" evidence is for the whole protein
A doping-control paper describes TB-500 as a veterinary preparation containing a synthetic version of the peptide LKKTETQ, a segment of thymosin beta-4.[23]
The human trials found here test full-length thymosin beta-4, not the TB-500 fragment: a randomized trial in healthy volunteers found intravenous synthetic thymosin beta-4 well tolerated at doses of 42-1260 mg.[24]
What was tested on TB-500 itself
In a rat Achilles tendon study, maximum load to failure was higher in both treated groups and reached statistical significance only in the TB-500 group.[25]
The same study found that BPC-157 plus TB-500 did not add benefit beyond either agent alone.[25]
The human dry-eye trial of thymosin beta-4 missed both primary endpoints.[26]
In 96 heart-attack patients, thymosin beta-4 did not significantly change overall infarct area against placebo.[8]
Regulatory path and sport
Drugs@FDA has no TB-500 product.[4]
FDA removed TB-500 from category 2 after the nomination was withdrawn, and announced a PCAC consultation for July 23, 2026.[5]
On WADA's list, thymosin-beta-4 derivatives are prohibited and TB-500 is given by name as an example.[3]
Compared with
Common stacks
TB-500 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.
Common questions
Is TB-500 FDA approved?
No. TB-500 is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee voted 8–6 in July 2026 to add it to the 503A compounding list. That vote is not final.
Is TB-500 banned in sport?
Yes. Prohibited by WADA (S2.3), so it is prohibited at all times for tested athletes.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is TB-500?
A synthetic version of LKKTETQ, the actin-binding region of thymosin beta-4.[23]
What does TB-500 do?
In a rat tendon study it raised load to failure; no human trial of TB-500 itself was found.[25]
What is the half-life of TB-500?
No TB-500 half-life exists in the cached literature; a mouse study of full-length thymosin beta-4 saw serum levels rise starting 2 min after injection and last 40 min.[27]
Is there oral TB-500?
No oral human study was found; the doping-control work was in horses.[23]
What safety risks did FDA cite for TB-500?
In its safety-risk entry, which has since been dropped, FDA said compounded versions may risk an immune response for certain routes because of aggregation and impurities. It added that it found no human exposure data and lacked key safety information, including whether the peptide would harm people.[28]
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "TB-500" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 5US compounding: TB-500 (thymosin beta-4 fragment) was removed from FDA's 503A category 2 after the nominator withdrew; FDA announced a PCAC consultation on 23 July 2026.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 6World Anti-Doping Code: Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 7Thymosin Beta-4 Induces Mouse Hair Growth.PloS one · 2015PMID 26083021Accessed 2 Oct 2026
- 8Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 9PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 17FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 18Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 19Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 20The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
- 21PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 22PubMed search: ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 23Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 24A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.Annals of the New York Academy of Sciences · 2010PMID 20536472Accessed 2 Oct 2026
- 25Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 26Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 27Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice.International journal of immunopharmacology · 1997PMID 9226473Accessed 2 Oct 2026
- 28Official web pageOfficial web page · web page
Found an error? Report a correction.